Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer | Zendy

Wei Zhao | Zendy; Lige Qiu | Zendy; Huajiang Liu | Zendy; Ying Xu | Zendy; Meixiao Zhan | Zendy; Wei Zhang | Zendy; Yongjie Xin | Zendy; Xu He | Zendy; Xiangyu Yang | Zendy; Jing Bai | Zendy; Jing Xiao | Zendy; Yanfang Guan | Zendy; Qiyang Li | Zendy; Lianpeng Chang | Zendy; Xin Yi | Zendy; Yong Li | Zendy; Xudong Chen | Zendy; Ligong Lu | Zendy

Open Access

Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer

Author(s) -

Wei Zhao,

Lige Qiu,

Huajiang Liu,

Ying Xu,

Meixiao Zhan,

Wei Zhang,

Yongjie Xin,

Xu He,

Xiangyu Yang,

Jing Bai,

Jing Xiao,

Yanfang Guan,

Qiyang Li,

Lianpeng Chang,

Xin Yi,

Yong Li,

Xudong Chen,

Ligong Lu

Publication year - 2020

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo-20-409

Subject(s) - medicine , biomarker , liver cancer , oncology , circulating tumor dna , targeted therapy , liquid biopsy , cancer , stage (stratigraphy) , response evaluation criteria in solid tumors , chemotherapy , progressive disease , paleontology , biochemistry , chemistry , biology

Imaging and alpha fetoprotein (AFP) measurement are used as surveillance methods during interventional therapy in patients with unresectable liver cancer, but their accuracy has been challenged in patients receiving drug perfusion therapy. Circulating tumor DNA (ctDNA) can reflect tumor load and treatment efficacy. Studies of the prognostic value of ctDNA in unresectable liver cancer are needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research